APO Research
Talk to an analyst

APO RESEARCH · REPORT

LFA-based Cardiac

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.

Selected research

Market Analysis & Forecast

Global LFA-based Cardiac Market Analysis and Forecast 2026-2032

28 December 2025193 pages

Choose your research edition.

Industry ResearchLFA-based Cardiac Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal LFA-based Cardiac Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal LFA-based Cardiac Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal LFA-based Cardiac Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal LFA-based Cardiac Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.

The industry's leading producers are Roche, Abbott and Siemens, with revenues of 26.24%, 16.11% and 11.04% respectively in 2019.

Read the full market overview

Report Includes

This report presents an overview of global market for LFA-based Cardiac, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of LFA-based Cardiac, also provides the revenue of main regions and countries. Of the upcoming market potential for LFA-based Cardiac, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the LFA-based Cardiac revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global LFA-based Cardiac market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for LFA-based Cardiac revenue, projected growth trends, production technology, application and end-user industry.

LFA-based Cardiac Segment by Company

Roche

Abbott

Siemens

Danaher

Bio-Rad Laboratories

BioMérieux

Thermo Fisher

Ortho Clinical Diagnostics

LSI Medience Corporation

Randox laboratories

Wondfo Biotech

LFA-based Cardiac Segment by Type

Troponin I

Troponin T

CK-MB

Myoglobin

Others

LFA-based Cardiac Segment by Application

Laboratory Testing

Point-of-care Testing

LFA-based Cardiac Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LFA-based Cardiac market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of LFA-based Cardiac and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LFA-based Cardiac.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of LFA-based Cardiac in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of LFA-based Cardiac company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, LFA-based Cardiac revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global LFA-based Cardiac Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Troponin I Major Player Table 3. Troponin T Major Player Table 4. CK-MB Major Player Table 5. Myoglobin Major Player Table 6. Others Major Player Table 7. Global LFA-based Cardiac Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Laboratory Testing Major Player Table 9. Point-of-care Testing Major Player Table 10. LFA-based Cardiac Industry Trends Table 11. LFA-based Cardiac Industry Drivers Table 12. LFA-based Cardiac Industry Opportunities and Challenges Table 13. LFA-based Cardiac Industry Restraints Table 14. Global LFA-based Cardiac Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global LFA-based Cardiac Market Size by Region (2021-2026) & (US$ Million) Table 16. Global LFA-based Cardiac Market Share by Region (2021-2026) Table 17. Global LFA-based Cardiac Market Size by Region (2027-2032) & (US$ Million) Table 18. Global LFA-based Cardiac Market Share by Region (2027-2032) Table 19. Global LFA-based Cardiac Revenue by Players (US$ Million) & (2021-2026) Table 20. Global LFA-based Cardiac Revenue Market Share by Players (2021-2026) Table 21. Global LFA-based Cardiac Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global LFA-based Cardiac Key Players Headquarters & Area Served Table 23. Global LFA-based Cardiac Players, Product Type & Application Table 24. Global LFA-based Cardiac Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global LFA-based Cardiac by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global LFA-based Cardiac Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 29. Global LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 30. Global LFA-based Cardiac Revenue Market Share by Type (2021-2026) Table 31. Global LFA-based Cardiac Revenue Market Share by Type (2027-2032) Table 32. Global LFA-based Cardiac Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 34. Global LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 35. Global LFA-based Cardiac Revenue Market Share by Application (2021-2026) Table 36. Global LFA-based Cardiac Revenue Market Share by Application (2027-2032) Table 37. Roche Company Information Table 38. Roche Business Overview Table 39. Roche LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Roche LFA-based Cardiac Product Portfolio Table 41. Roche Recent Development Table 42. Abbott Company Information Table 43. Abbott Business Overview Table 44. Abbott LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Abbott LFA-based Cardiac Product Portfolio Table 46. Abbott Recent Development Table 47. Siemens Company Information Table 48. Siemens Business Overview Table 49. Siemens LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Siemens LFA-based Cardiac Product Portfolio Table 51. Siemens Recent Development Table 52. Danaher Company Information Table 53. Danaher Business Overview Table 54. Danaher LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Danaher LFA-based Cardiac Product Portfolio Table 56. Danaher Recent Development Table 57. Bio-Rad Laboratories Company Information Table 58. Bio-Rad Laboratories Business Overview Table 59. Bio-Rad Laboratories LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bio-Rad Laboratories LFA-based Cardiac Product Portfolio Table 61. Bio-Rad Laboratories Recent Development Table 62. BioMérieux Company Information Table 63. BioMérieux Business Overview Table 64. BioMérieux LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. BioMérieux LFA-based Cardiac Product Portfolio Table 66. BioMérieux Recent Development Table 67. Thermo Fisher Company Information Table 68. Thermo Fisher Business Overview Table 69. Thermo Fisher LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Thermo Fisher LFA-based Cardiac Product Portfolio Table 71. Thermo Fisher Recent Development Table 72. Ortho Clinical Diagnostics Company Information Table 73. Ortho Clinical Diagnostics Business Overview Table 74. Ortho Clinical Diagnostics LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio Table 76. Ortho Clinical Diagnostics Recent Development Table 77. LSI Medience Corporation Company Information Table 78. LSI Medience Corporation Business Overview Table 79. LSI Medience Corporation LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. LSI Medience Corporation LFA-based Cardiac Product Portfolio Table 81. LSI Medience Corporation Recent Development Table 82. Randox laboratories Company Information Table 83. Randox laboratories Business Overview Table 84. Randox laboratories LFA-based Cardiac Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Randox laboratories LFA-based Cardiac Product Portfolio Table 86. Randox laboratories Recent Development Table 87. Wondfo Biotech Company Information Table 88. Wondfo Biotech Business Overview Table 89. Wondfo Biotech LFA-based Cardiac Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 90. Wondfo Biotech LFA-based Cardiac Product Portfolio Table 91. Wondfo Biotech Recent Development Table 92. North America LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 93. North America LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 94. North America LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 95. North America LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 96. North America LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America LFA-based Cardiac Revenue by Country (2021-2026) & (US$ Million) Table 98. North America LFA-based Cardiac Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe LFA-based Cardiac Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe LFA-based Cardiac Revenue by Country (US$ Million) & (2027-2032) Table 106. China LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 107. China LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 108. China LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 109. China LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia LFA-based Cardiac Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia LFA-based Cardiac Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia LFA-based Cardiac Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA LFA-based Cardiac Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA LFA-based Cardiac Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA LFA-based Cardiac Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA LFA-based Cardiac Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA LFA-based Cardiac Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA LFA-based Cardiac Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. LFA-based Cardiac Image Figure 2. Global LFA-based Cardiac Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global LFA-based Cardiac Market Size Share 2021 VS 2025 VS 2032 Figure 4. Troponin I Image Figure 5. Troponin T Image Figure 6. CK-MB Image Figure 7. Myoglobin Image Figure 8. Others Image Figure 9. Global LFA-based Cardiac Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global LFA-based Cardiac Market Size Share 2021 VS 2025 VS 2032 Figure 11. Laboratory Testing Image Figure 12. Point-of-care Testing Image Figure 13. Global LFA-based Cardiac Market Size (US$ Million) & (2021-2032) Figure 14. Global LFA-based Cardiac Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global LFA-based Cardiac Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global LFA-based Cardiac Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global LFA-based Cardiac Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global LFA-based Cardiac Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global LFA-based Cardiac Revenue Market Share by Type (2021-2032) Figure 21. Global LFA-based Cardiac Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global LFA-based Cardiac Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global LFA-based Cardiac Revenue Market Share by Application (2021-2032) Figure 24. North America LFA-based Cardiac Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America LFA-based Cardiac Revenue Share by Type (2021-2032) Figure 26. North America LFA-based Cardiac Revenue Share by Application (2021-2032) Figure 27. North America LFA-based Cardiac Revenue Share by Country (2021-2032) Figure 28. United States LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe LFA-based Cardiac Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe LFA-based Cardiac Revenue Share by Type (2021-2032) Figure 33. Europe LFA-based Cardiac Revenue Share by Application (2021-2032) Figure 34. Europe LFA-based Cardiac Revenue Share by Country (2021-2032) Figure 35. Germany LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China LFA-based Cardiac Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China LFA-based Cardiac Revenue Share by Type (2021-2032) Figure 45. China LFA-based Cardiac Revenue Share by Application (2021-2032) Figure 46. Asia LFA-based Cardiac Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia LFA-based Cardiac Revenue Share by Type (2021-2032) Figure 48. Asia LFA-based Cardiac Revenue Share by Application (2021-2032) Figure 49. Asia LFA-based Cardiac Revenue Share by Region (2021-2032) Figure 50. Japan LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA LFA-based Cardiac Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA LFA-based Cardiac Revenue Share by Type (2021-2032) Figure 58. SAMEA LFA-based Cardiac Revenue Share by Application (2021-2032) Figure 59. SAMEA LFA-based Cardiac Revenue Share by Country (2021-2032) Figure 60. Brazil LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt LFA-based Cardiac Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Troponin I
  • Troponin T
  • CK-MB
  • Myoglobin
  • Others
Applications
  • Laboratory Testing
  • Point-of-care Testing
Companies covered
  • Roche
  • Abbott
  • Siemens
  • Danaher
  • Bio-Rad Laboratories
  • BioMérieux
  • Thermo Fisher
  • Ortho Clinical Diagnostics
  • LSI Medience Corporation
  • Randox laboratories
  • Wondfo Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 LFA-based Cardiac Market by Type
  3. 1.2.1 Global LFA-based Cardiac Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Troponin I
  5. 1.2.3 Troponin T
  6. 1.2.4 CK-MB
  7. 1.2.5 Myoglobin
  8. 1.2.6 Others
  9. 1.3 LFA-based Cardiac Market by Application
  10. 1.3.1 Global LFA-based Cardiac Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Laboratory Testing
  12. 1.3.3 Point-of-care Testing
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 LFA-based Cardiac Market Dynamics
  1. 2.1 LFA-based Cardiac Industry Trends
  2. 2.2 LFA-based Cardiac Industry Drivers
  3. 2.3 LFA-based Cardiac Industry Opportunities and Challenges
  4. 2.4 LFA-based Cardiac Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global LFA-based Cardiac Market Perspective (2021-2032)
  2. 3.2 Global LFA-based Cardiac Growth Trends by Region
  3. 3.2.1 Global LFA-based Cardiac Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global LFA-based Cardiac Market Size by Region (2021-2026)
  5. 3.2.3 Global LFA-based Cardiac Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global LFA-based Cardiac Revenue by Players
  2. 4.1.1 Global LFA-based Cardiac Revenue by Players (2021-2026)
  3. 4.1.2 Global LFA-based Cardiac Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global LFA-based Cardiac Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global LFA-based Cardiac Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global LFA-based Cardiac Key Players Headquarters & Area Served
  7. 4.4 Global LFA-based Cardiac Players, Product Type & Application
  8. 4.5 Global LFA-based Cardiac Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global LFA-based Cardiac Market CR5 and HHI
  11. 4.6.3 2025 LFA-based Cardiac Tier 1, Tier 2, and Tier 3
5 LFA-based Cardiac Market Size by Type
  1. 5.1 Global LFA-based Cardiac Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global LFA-based Cardiac Revenue by Type (2021-2032)
  3. 5.3 Global LFA-based Cardiac Revenue Market Share by Type (2021-2032)
6 LFA-based Cardiac Market Size by Application
  1. 6.1 Global LFA-based Cardiac Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global LFA-based Cardiac Revenue by Application (2021-2032)
  3. 6.3 Global LFA-based Cardiac Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche LFA-based Cardiac Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Abbott
  8. 7.2.1 Abbott Company Information
  9. 7.2.2 Abbott Business Overview
  10. 7.2.3 Abbott LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Abbott LFA-based Cardiac Product Portfolio
  12. 7.2.5 Abbott Recent Developments
  13. 7.3 Siemens
  14. 7.3.1 Siemens Company Information
  15. 7.3.2 Siemens Business Overview
  16. 7.3.3 Siemens LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Siemens LFA-based Cardiac Product Portfolio
  18. 7.3.5 Siemens Recent Developments
  19. 7.4 Danaher
  20. 7.4.1 Danaher Company Information
  21. 7.4.2 Danaher Business Overview
  22. 7.4.3 Danaher LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Danaher LFA-based Cardiac Product Portfolio
  24. 7.4.5 Danaher Recent Developments
  25. 7.5 Bio-Rad Laboratories
  26. 7.5.1 Bio-Rad Laboratories Company Information
  27. 7.5.2 Bio-Rad Laboratories Business Overview
  28. 7.5.3 Bio-Rad Laboratories LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bio-Rad Laboratories LFA-based Cardiac Product Portfolio
  30. 7.5.5 Bio-Rad Laboratories Recent Developments
  31. 7.6 BioMérieux
  32. 7.6.1 BioMérieux Company Information
  33. 7.6.2 BioMérieux Business Overview
  34. 7.6.3 BioMérieux LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  35. 7.6.4 BioMérieux LFA-based Cardiac Product Portfolio
  36. 7.6.5 BioMérieux Recent Developments
  37. 7.7 Thermo Fisher
  38. 7.7.1 Thermo Fisher Company Information
  39. 7.7.2 Thermo Fisher Business Overview
  40. 7.7.3 Thermo Fisher LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Thermo Fisher LFA-based Cardiac Product Portfolio
  42. 7.7.5 Thermo Fisher Recent Developments
  43. 7.8 Ortho Clinical Diagnostics
  44. 7.8.1 Ortho Clinical Diagnostics Company Information
  45. 7.8.2 Ortho Clinical Diagnostics Business Overview
  46. 7.8.3 Ortho Clinical Diagnostics LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio
  48. 7.8.5 Ortho Clinical Diagnostics Recent Developments
  49. 7.9 LSI Medience Corporation
  50. 7.9.1 LSI Medience Corporation Company Information
  51. 7.9.2 LSI Medience Corporation Business Overview
  52. 7.9.3 LSI Medience Corporation LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  53. 7.9.4 LSI Medience Corporation LFA-based Cardiac Product Portfolio
  54. 7.9.5 LSI Medience Corporation Recent Developments
  55. 7.10 Randox laboratories
  56. 7.10.1 Randox laboratories Company Information
  57. 7.10.2 Randox laboratories Business Overview
  58. 7.10.3 Randox laboratories LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Randox laboratories LFA-based Cardiac Product Portfolio
  60. 7.10.5 Randox laboratories Recent Developments
  61. 7.11 Wondfo Biotech
  62. 7.11.1 Wondfo Biotech Company Information
  63. 7.11.2 Wondfo Biotech Business Overview
  64. 7.11.3 Wondfo Biotech LFA-based Cardiac Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Wondfo Biotech LFA-based Cardiac Product Portfolio
  66. 7.11.5 Wondfo Biotech Recent Developments
8 North America
  1. 8.1 North America LFA-based Cardiac Revenue (2021-2032)
  2. 8.2 North America LFA-based Cardiac Revenue by Type (2021-2032)
  3. 8.2.1 North America LFA-based Cardiac Revenue by Type (2021-2026)
  4. 8.2.2 North America LFA-based Cardiac Revenue by Type (2027-2032)
  5. 8.3 North America LFA-based Cardiac Revenue Share by Type (2021-2032)
  6. 8.4 North America LFA-based Cardiac Revenue by Application (2021-2032)
  7. 8.4.1 North America LFA-based Cardiac Revenue by Application (2021-2026)
  8. 8.4.2 North America LFA-based Cardiac Revenue by Application (2027-2032)
  9. 8.5 North America LFA-based Cardiac Revenue Share by Application (2021-2032)
  10. 8.6 North America LFA-based Cardiac Revenue by Country
  11. 8.6.1 North America LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America LFA-based Cardiac Revenue by Country (2021-2026)
  13. 8.6.3 North America LFA-based Cardiac Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe LFA-based Cardiac Revenue (2021-2032)
  2. 9.2 Europe LFA-based Cardiac Revenue by Type (2021-2032)
  3. 9.2.1 Europe LFA-based Cardiac Revenue by Type (2021-2026)
  4. 9.2.2 Europe LFA-based Cardiac Revenue by Type (2027-2032)
  5. 9.3 Europe LFA-based Cardiac Revenue Share by Type (2021-2032)
  6. 9.4 Europe LFA-based Cardiac Revenue by Application (2021-2032)
  7. 9.4.1 Europe LFA-based Cardiac Revenue by Application (2021-2026)
  8. 9.4.2 Europe LFA-based Cardiac Revenue by Application (2027-2032)
  9. 9.5 Europe LFA-based Cardiac Revenue Share by Application (2021-2032)
  10. 9.6 Europe LFA-based Cardiac Revenue by Country
  11. 9.6.1 Europe LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe LFA-based Cardiac Revenue by Country (2021-2026)
  13. 9.6.3 Europe LFA-based Cardiac Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China LFA-based Cardiac Revenue (2021-2032)
  2. 10.2 China LFA-based Cardiac Revenue by Type (2021-2032)
  3. 10.2.1 China LFA-based Cardiac Revenue by Type (2021-2026)
  4. 10.2.2 China LFA-based Cardiac Revenue by Type (2027-2032)
  5. 10.3 China LFA-based Cardiac Revenue Share by Type (2021-2032)
  6. 10.4 China LFA-based Cardiac Revenue by Application (2021-2032)
  7. 10.4.1 China LFA-based Cardiac Revenue by Application (2021-2026)
  8. 10.4.2 China LFA-based Cardiac Revenue by Application (2027-2032)
  9. 10.5 China LFA-based Cardiac Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia LFA-based Cardiac Revenue (2021-2032)
  2. 11.2 Asia LFA-based Cardiac Revenue by Type (2021-2032)
  3. 11.2.1 Asia LFA-based Cardiac Revenue by Type (2021-2026)
  4. 11.2.2 Asia LFA-based Cardiac Revenue by Type (2027-2032)
  5. 11.3 Asia LFA-based Cardiac Revenue Share by Type (2021-2032)
  6. 11.4 Asia LFA-based Cardiac Revenue by Application (2021-2032)
  7. 11.4.1 Asia LFA-based Cardiac Revenue by Application (2021-2026)
  8. 11.4.2 Asia LFA-based Cardiac Revenue by Application (2027-2032)
  9. 11.5 Asia LFA-based Cardiac Revenue Share by Application (2021-2032)
  10. 11.6 Asia LFA-based Cardiac Revenue by Country
  11. 11.6.1 Asia LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia LFA-based Cardiac Revenue by Country (2021-2026)
  13. 11.6.3 Asia LFA-based Cardiac Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA LFA-based Cardiac Revenue (2021-2032)
  2. 12.2 SAMEA LFA-based Cardiac Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA LFA-based Cardiac Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA LFA-based Cardiac Revenue by Type (2027-2032)
  5. 12.3 SAMEA LFA-based Cardiac Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA LFA-based Cardiac Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA LFA-based Cardiac Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA LFA-based Cardiac Revenue by Application (2027-2032)
  9. 12.5 SAMEA LFA-based Cardiac Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA LFA-based Cardiac Revenue by Country
  11. 12.6.1 SAMEA LFA-based Cardiac Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA LFA-based Cardiac Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA LFA-based Cardiac Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst